FairJourney Biologics

IONTAS and FairJourney Biologics Discover SARS-CoV2 Neutralising Antibodies with Picomolar Potency

Panel of 15 potent antibodies selected that are optimally suited to clinical development and manufacturing Monoclonal antibodies have the potential to both treat infected patients and provide protection to the “at risk” population during the pandemic Viral neutralisation data independently verified by the National Institute for Biological Standards and Control (NIBSC) Project is part of an… read more

FairJourney Biologics joins forces with Iontas to create a global leader in outsourced antibody discovery services

FairJourney’s combination with Iontas creates a leading global antibody discovery CRO with an international footprint FairJourney’s unique antibody discovery libraries and service portfolio to be complemented by Iontas’ proprietary mammalian display technology Group to have an unparalleled service and technology offering across antibody discovery, engineering, characterisation, and manufacturing services London, UK – Global Healthcare Opportunities, or… read more

Leading global antibody discovery companies FairJourney Biologics and Iontas announce partnership in search for SARS-CoV-2 treatment

London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, FairJourney Biologics, regarding the partnership with Iontas in search for SARS-CoV-2 treatment. FairJourney Biologics (Porto, Portugal) and Iontas (Cambridge, UK) today announce a partnership to expedite the identification of effective antibodies for… read more

Subscribe to our email alerts

Email updates